Numerai GP LLC Trims Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Numerai GP LLC cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 54.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,042 shares of the life sciences company's stock after selling 3,676 shares during the period. Numerai GP LLC's holdings in Illumina were worth $407,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of ILMN. OMERS ADMINISTRATION Corp raised its holdings in shares of Illumina by 20.1% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 6,648 shares of the life sciences company's stock valued at $888,000 after purchasing an additional 1,114 shares during the last quarter. Meridiem Capital Partners LP purchased a new stake in Illumina in the 4th quarter valued at about $12,712,000. Laurion Capital Management LP bought a new position in shares of Illumina during the 4th quarter worth approximately $950,000. Integral Health Asset Management LLC purchased a new position in shares of Illumina in the 4th quarter worth approximately $5,345,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Illumina in the 4th quarter worth approximately $1,314,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Ankur Dhingra purchased 6,100 shares of the business's stock in a transaction on Monday, May 12th. The shares were acquired at an average price of $81.21 per share, with a total value of $495,381.00. Following the acquisition, the chief financial officer now directly owns 24,906 shares in the company, valued at approximately $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 2.60% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on ILMN. TD Cowen cut Illumina from a "buy" rating to a "hold" rating and cut their price objective for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. JPMorgan Chase & Co. decreased their target price on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Canaccord Genuity Group reduced their price target on Illumina from $92.00 to $87.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Hsbc Global Res cut Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Finally, Robert W. Baird decreased their price target on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $128.15.

Illumina Price Performance

ILMN traded down $2.33 during midday trading on Wednesday, hitting $81.89. The stock had a trading volume of 575,997 shares, compared to its average volume of 2,310,084. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The business has a fifty day moving average of $78.46 and a 200 day moving average of $110.24. The company has a market cap of $12.96 billion, a P/E ratio of -10.63, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.01. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same period in the previous year, the firm posted $0.98 earnings per share. The firm's revenue for the quarter was down 1.4% on a year-over-year basis. As a group, equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.